NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cleveland BioLabs, Inc. (NASDAQ: CBLI) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Cytocom, Inc.
Click here to learn more and participate in the action.
On October 20, 2020, Cleveland BioLabs announced that it had signed an agreement to be acquired by Cytocom. Pursuant to the merger agreement, CBLI stockholders will own approximately 39% of the new company.
Bragar Eagel & Squire is concerned that Cleveland BioLabs’ board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Cleveland BioLabs’ stockholders.
If you own shares of Cleveland BioLabs and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at email@example.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.